Dr. Ada Braun Joins Biothera as Chief Medical Officer

EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today the appointment of Ada H. Braun, M.D., Ph.D. as Chief Medical Officer responsible for the clinical and regulatory development of Imprime PGG®, the company's Phase 3 cancer immunotherapy drug. Most recently, Dr. Braun was Executive Medical Director, Global Development, Hematology/Oncology at Amgen, Inc.

Dr. Braun has extensive experience in the treatment of both liquid and solid tumors and the development of novel biologic therapeutics. At Amgen, she led the clinical development of denosumab (XGEVA®, Prolia®), a monoclonal antibody designed to improve bone health in patients with osteoporosis, cancer treatment-induced bone loss, and advanced malignancies involving bone.

"Dr. Braun's clinical development expertise and successful track record of working with the FDA to obtain approval for oncology drugs make her an excellent candidate to lead the development of Imprime PGG," said Dan Conners, president of Biothera's Pharmaceutical Group.

"I am excited about this incredible opportunity. Biothera has been a pioneer in cancer immunotherapy and is the preeminent leader in innate immune modulation," said Dr. Braun. "Imprime PGG's unique mechanism of action and promising clinical data support its broad-base potential. I look forward to leading its development."

Dr. Braun held several senior clinical development positions in hematology and oncology at Amgen. Before that she conducted translational oncology research at Vanderbilt University Medical Center. Dr. Braun has an international medical experience and has practiced medicine in Germany, France, Ecuador and South Africa.

Dr. Braun received her M.D. from Georg-August-Universität, Göttingen, Germany, and Université Paris-XI, Paris, France and a Ph.D. from the West German Cancer Center, University of Duisburg-Essen Medical School, Essen, Germany. She completed a postdoctoral fellowship in Cell and Developmental Biology and Cancer Biology at Vanderbilt University, Nashville.

A frequent speaker and author of numerous research articles, Dr. Braun also has served on the editorial board of medical and scientific journals.

About Imprime PGG®
Imprime PGG is a novel immunomodulatory drug in development as a cancer therapy. Imprime PGG has been shown to bind to neutrophils and monocytes and redirect their killing ability to reduce tumor growth and enhance long-term survival. This targeted mechanism is synergistic with multiple anti-tumor monoclonal antibodies, providing the potential to improve patient outcomes in a wide range of cancer indications. Imprime PGG has demonstrated marked improvements in response rates in multiple clinical trials for non-small cell lung cancer (NSCLC)colorectal cancer and chronic lymphocytic leukemia. Imprime PGG is currently in a Phase 3 clinical trial for advanced colorectal cancer and a second Phase 2 NSCLC study.

For more information, visit our website at www.biothera.com/pharma.

About Biothera, the Immune Health Company
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer.


Biothera, the Immune Health Company
David Walsh, 651-256-4606
VP Communications
[email protected]